SCHEMBL515242

SCHEMBL515242

CCCC(CCC)C([O])=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.60
HDAC2 Q92769 3/20 0.60
CHRM1 P11229 1/20 0.60
AKR1A1 P14550 1/20 0.60
CHRM3 P20309 1/20 0.60
HTR2A P28223 1/20 0.60
HTR2C P28335 1/20 0.60
ADRA1A P35348 1/20 0.60
HRH1 P35367 1/20 0.60
DRD3 P35462 1/20 0.60
SLC6A3 Q01959 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
TSHR P16473 3/20 0.57
CYP3A4 P08684 2/20 0.57
NFKB1 P19838 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
HDAC7 Q8WUI4 3/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC6 Q9UBN7 3/20 0.52
HDAC9 Q9UKV0 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8811133 0.89 CA2 (0.54) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL275821 0.88
SCHEMBL8811451 0.87 CA2 (0.52) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL277259 0.85 CA2 (0.55) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL2352379 0.82 CA2 (0.58) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL20490025 0.82 CHRM1 (0.48) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL28210380 0.80 HDAC1 (0.46) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL7701880 0.78 CA2 (0.59) GRIK1SLC1A2SLC1A1GRIK2CA2
SCHEMBL919412 0.78 CA2 (0.59) GRIK1SLC1A2SLC1A1GRIK2CA2
SCHEMBL919763 0.78 CA2 (0.59) GRIK1SLC1A2SLC1A1GRIK2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117440961-A Nucleoside medicine for treating or preventing coronavirus infection and application thereof 北京沐华生物科技有限责任公司 2024-01-23 CN claimed
WO-2023207942-A1 NUCLEOSIDE DRUG FOR TREATING OR PREVENTING CORONAVIRUS INFECTION, AND USE THEREOF 北京沐华生物科技有限责任公司 2023-11-02 WO claimed
US-20230338409-A1 NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES MIRACURE BIOTECHNOLOGY LTD (CN) 2023-10-26 US claimed
CN-117440961-A Nucleoside medicine for treating or preventing coronavirus infection and application thereof 北京沐华生物科技有限责任公司 2024-01-23 CN disclosed
WO-2023207942-A1 NUCLEOSIDE DRUG FOR TREATING OR PREVENTING CORONAVIRUS INFECTION, AND USE THEREOF 北京沐华生物科技有限责任公司 2023-11-02 WO disclosed
US-20230338409-A1 NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES MIRACURE BIOTECHNOLOGY LTD (CN) 2023-10-26 US disclosed
EP-3372581-B1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL DAIKIN IND LTD (JP) 2021-06-23 EP disclosed
US-10894770-B2 Fullerene derivative and n-type semiconductor material DAIKIN INDUSTRIES, LTD. (JP) 2021-01-19 US disclosed
US-20180282274-A1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL DAIKIN INDUSTRIES, LTD. (JP) 2018-10-04 US disclosed
EP-3372581-A1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL Daikin Industries, Ltd. (JP) 2018-09-12 EP disclosed
CN-104955926-B For improving the lubricant compositions for including epoxide compound of fluoropolymer sealant compatibility 巴斯夫欧洲公司 2018-06-22 CN disclosed
WO-2014184071-A1 MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES SYNGENTA LIMITED (GB) 2014-11-20 WO disclosed
WO-2014184070-A1 MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES SYNGENTA LIMITED (GB) 2014-11-20 WO disclosed
EP-2420493-A1 HALOALKYLSULFONANILIDE DERIVATIVE Nissan Chemical Industries, Ltd. (JP) 2012-02-22 EP disclosed
US-20120029187-A1 HALOALKYLSULFONANILIDE DERIVATIVE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-02-02 US disclosed
EP-2336104-A1 ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE Nissan Chemical Industries, Ltd. (JP) 2011-06-22 EP disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
US-4261987-A ANTICONVULSANTS GEROT PHARMAZEUTIKA GESELLSCHAFT M.B.H. (AT) 1981-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10894770-B2 Fullerene derivative and n-type semiconductor material SUN2, NES, L1CAM HDAC1 4044/4885HDAC2 3787/4885CHRM1 51/4885
US-20180282274-A1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL SUN2, NES, L1CAM HDAC1 4044/4885HDAC2 3787/4885CHRM1 51/4885
US-20120029187-A1 HALOALKYLSULFONANILIDE DERIVATIVE CBR3, CBR1, HDHD5 HDAC1 1679/4885HDAC2 2358/4885CHRM1 75/4885
US-20230338409-A1 NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES PNP, MTAP, TYMP HDAC1 3090/4885HDAC2 2884/4885CHRM1 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.